The silence of MUC2 mRNA induced by promoter hypermethylation associated with HBV in Hepatocellular Carcinoma

11Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: To evaluate the promoter methylation status of MUC2 gene and mRNA expression in patients with hepatocellular carcinoma.Methods: We analyzed MUC2 methylation by MSP, and MUC2 mRNA by real-time PCR in 74 HCC.Results: MUC2 mRNA were lower in HCC tissues (Mean -ΔCt = -4.70) than that in Non-HCC tissues (Mean -ΔCt = -2.98). Expression of MUC2 was elevated in only 23 (31.08%) of the 74 HCC patients. MUC2 promoter was hypermethylated in 62.2% (46/74) of HCCs, and in only 18.9% (14/74) of non-tumor samples. MUC2 mRNA were lower in HCC patients with hypermethylation (Mean -ΔΔCt = -2.25) than those with demethylation (Mean -ΔΔCt = -0.22), and there is a decreased tendency for MUC2 mRNA in HCC patients with promoter hypermethylation (p = 0.011). There was a significantly correlation found between MUC2 mRNA and HBV and AFP in HCC. The loss of MUC2 mRNA and hypermethylation could be poor prognostic factors. After treated by 5-Aza-CdR and TSA, we found that MUC2 mRNA induced significantly in 7721, Huh7 and HepG2 cells.Conclusion: The results suggested that MUC2 mRNA silenced by promoter hypermethylation is associated with high levels HBV in HCC. © 2013 Ling et al; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Ling, Y., Zhu, J., Gao, L., Liu, Y., Zhu, C., Li, R., … Zhang, C. (2013). The silence of MUC2 mRNA induced by promoter hypermethylation associated with HBV in Hepatocellular Carcinoma. BMC Medical Genetics, 14(1). https://doi.org/10.1186/1471-2350-14-14

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free